KT-621 clinical trials
Also written KT-621.
How each study uses KT-621 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KT-621 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KT-621
- 6
Studies by the year they started
6 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Kymera Therapeutics, Inc. (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test KT-621.
- Apr 2027A Study to Evaluate Different Oral Formulations of KT-621Phase 1 · Kymera Therapeutics, Inc.
- Jun 2027A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisPhase 2 · Kymera Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses KT-621 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate Different Oral Formulations of KT-621RecruitingPhase 1Kymera Therapeutics, Inc.NCT07823205Written as KT-621
- A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma StudyRecruitingPhase 2Kymera Therapeutics, Inc.NCT07677059Written as KT-621
- A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaRecruitingPhase 2Kymera Therapeutics, Inc.NCT07323654Written as KT-621
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisActive, not recruitingPhase 2Kymera Therapeutics, Inc.NCT07217015Written as KT-621
- Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)CompletedPhase 1Kymera Therapeutics, Inc.NCT06945458Written as KT-621
- First-in-human Study of Orally Administered KT-621 in Healthy Adult ParticipantsCompletedPhase 1Kymera Therapeutics, Inc.NCT06673667Written as KT-621